Get started
Author

Filipa Bica Simões

Observed names: F B Simões, F. Bica Simões, F.B. Simões, Filipa B Simões, Filipa B. Simões, Filipa Simões, Simões, F.B., Simões, Filipa Bica
Observed institutions: University of Lisbon, Novo Nordisk Foundation, Rigshospitalet, Nordic Bioscience (Denmark), University of Regensburg, Technical University of Denmark
ORCID: 0000-0003-2010-1282
Observed ORCID: 0000-0003-2010-1282
OpenAlex ID: A5036921451
CFTR supports cell death through ROS-dependent activation of TMEM16F (anoctamin 6)
2017 · Filipa Simões, Jiraporn Ousingsawat, et al. · Pflügers Archiv - European Journal of Physiology · 43
TMEM16A chloride channel does not drive mucus production
2019 · Filipa B Simões, Margarida C Quaresma, et al. · Life Science Alliance · 33
PDF
Metabolic specialization drives reduced pathogenicity in Pseudomonas aeruginosa isolates from cystic fibrosis patients
2024 · Bjarke H. Pedersen, Filipa B. Simões, et al. · PLoS Biology · 20
Cross-talk of inflammatory mediators and airway epithelium reveals the cystic fibrosis transmembrane conductance regulator as a major target
2021 · Filipa B. Simões, Arthur Kmit, et al. · ERJ Open Research · 20
PDF
Impact of KLF4 on Cell Proliferation and Epithelial Differentiation in the Context of Cystic Fibrosis
2020 · Luís Sousa, Ines Pankonien, et al. · International Journal of Molecular Sciences · 14
PDF
Establishment of a 3D-Printed Tissue-on-a-Chip Model for Live Imaging of Bacterial Infections
2024 · Albert Fuglsang-Madsen, Janus Anders Juul Haagensen, et al. · Advances in experimental medicine and biology · 5
PDF
Cell-type-independent infection dynamics of clinical Pseudomonas aeruginosa isolates in human airway epithelial models
2026 · Claudia Antonella Colque, Signe Lolle, et al. · Cell Reports · 4
Basement membrane repair response biomarker PRO-C4 predicts progression in idiopathic pulmonary fibrosis: analysis of the PFBIO and PROFILE cohorts
2025 · Jannie M B Sand, Peder Frederiksen, et al. · Thorax · 4
PDF
Differential Effects of Antifibrotic Treatment on Outcome Prediction via Serial Matrix Metalloproteinase-Degraded C-Reactive Protein Neoepitope Levels in Idiopathic Pulmonary Fibrosis
2025 · Benjamin Seeliger, Jannik Ruwisch, et al. · CHEST Journal · 3
Type VI collagen is proportionally lower around airways and blood vessels in idiopathic pulmonary fibrosis
2026 · Helene Wallem Breisnes, Mehmet Nizamoglu, et al. · American Journal of Physiology-Cell Physiology · 1
Lung fibroblast activation protein expression is associated with extracellular matrix remodelling in post-acute sequelae of SARS-CoV-2
2026 · Niels J. Postma, Bram van Leer, et al. · ERJ Open Research · 1
Vimentin serum biomarkers are differentially related to disease progression in idiopathic pulmonary fibrosis (IPF)
2023 · Filipa B Simões, Nils Hoyer, et al. · European Respiratory Journal · 1
Type VI Collagen Formation Is Induced in a Scar-in-a-Jar Fibroblast Model Stimulated With a Combination of TGF-β and PDGF
2023 · F.B. Simões, M. Skarsfeldt, et al. · American Journal of Respiratory and Critical Care Medicine · 1
Early changes in type VI collagen synthesis (serum PRO-C6) are associated with distinct lung function trajectories in idiopathic pulmonary fibrosis
2026 · Jannie M. B. Sand, Sebastian H. Rode, et al. · European Respiratory Journal
Prognostic value of the fibrogenesis biomarker PRO-C3 in idiopathic pulmonary fibrosis cohorts with different severities and response to antifibrotic therapy
2026 · Filipa B Simões, Peder Fredriksen, et al. · European Respiratory Journal
Collagen remodeling is elevated in fibrotic hypersensitivity pneumonitis and may distinguish it from idiopathic pulmonary fibrosis
2026 · Georgia Christoforidou, Filipa Bica Simões, et al. · BMC Pulmonary Medicine
Circulating biomarkers reflecting type III, IV and VI collagen remodeling are present in lung tissue of patients with pulmonary fibrosis and non-fibrotic controls
2026 · Helene Wallem Breisnes, Sissel Kronborg-White, et al. · Scientific Reports
PDF
Fibroblast activity biomarkers are associated with mortality in severe COVID-19: a post-hoc analysis of a phase 2 clinical trial
2026 · Helene Wallem Breisnes, Filipa Bica Simões, et al. · Respiratory Research
Supplementary Material
2026 · Helene Wallem Breisnes, Mehmet Nizamoglu, et al. · Figshare
A74-02 Disrupted Type VI Collagen Localization Around Airways and Blood Vessels in the IPF Lung
2026 · H W Breisnes, M Nizamoglu, et al. · American Journal of Respiratory and Critical Care Medicine
D23-20 Systemic Markers of Type IV Collagen Remodeling Distinguish Idiopathic Pulmonary Fibrosis From Fibrotic Hypersensitivity Pneumonitis
2026 · G Christoforidou, S Kronborg-White, et al. · American Journal of Respiratory and Critical Care Medicine
Differential Effects of Antifibrotic Treatment on Outcome Prediction via Serial Matrix Metalloproteinase-Degraded C-Reactive Protein Neoepitope Levels in Idiopathic Pulmonary Fibrosis
2026 · Seeliger, Benjamin, Ruwisch, Jannik, et al. · Fraunhofer-Publica (Fraunhofer-Gesellschaft)
Tissue turnover biomarkers are associated with lung function and exercise capacity in idiopathic pulmonary fibrosis
2025 · Filipa B Simões, Nils Hoyer, et al. · European Respiratory Journal
Seralutinib decreases endotrophin (PRO-C6) production, a mediator of fibrosis and inflammation, in an in vitro model of pulmonary fibrosis
2025 · Zhaoqing Ding, Mark Kuipers-Skarsfeldt, et al. · European Respiratory Journal
Type III and VI Collagen Remodeling Biomarkers Have the Potential to Distinguish Between Idiopathic Pulmonary Fibrosis and Hypersensitivity Pneumonitis
2025 · G. Christoforidou, S. Duval Dræby, et al. · American Journal of Respiratory and Critical Care Medicine
Works count: 36
Citation count: 150
H-index: 5
I10-index: 5
Year
Topic
Type